Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2023-12-01 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司监事会关于《公司2023年第二期限制性股票激励计划（草案）》的核查意见
Governance Information Classification · 95% confidence The document is a supervisory board's verification opinion on a draft restricted stock incentive plan for 2023. It discusses compliance with relevant laws and regulations, qualifications of incentive recipients, and governance aspects related to the stock incentive plan. It does not contain financial statements or audit results, nor is it an announcement of voting results or a proxy solicitation. The content focuses on governance and supervisory review of a stock incentive plan, which aligns with governance-related filings. Given the nature of the document, it fits best under Governance Information (CGR). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the classification is CGR with high confidence.
2023-12-01 Chinese
圣湘生物科技股份有限公司新增认定核心技术人员及核心业务人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from the board of directors of 圣湘生物科技股份有限公司 regarding the addition of core technical and business personnel. It provides detailed personal resumes and shareholding information of these individuals. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content focuses on management personnel changes and related share incentive plans. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or key personnel.
2023-12-01 Chinese
圣湘生物科技股份有限公司第二届监事会2023年第十次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of 圣湘生物科技股份有限公司 (Shengxiang Bio). It details the approval of proposals related to a restricted stock incentive plan, including the plan draft, implementation assessment methods, and verification of the initial list of incentive recipients. The document includes voting results and mentions that these proposals will be submitted to the shareholders' meeting for approval. The content focuses on governance and management decisions rather than financial results or audit information. It is not a full report but a meeting resolution announcement related to management and governance matters. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 2259 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2023-12-01 Chinese
圣湘生物科技股份有限公司第二届董事会2023年第十二次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding several proposals, including a restricted stock incentive plan and the authorization to convene a shareholders' meeting. It details the board meeting date, attendance, voting results, and the need to submit these proposals to the shareholders' meeting for approval. The document does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is an official announcement of board decisions and upcoming shareholder meeting arrangements. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2023-12-01 Chinese
圣湘生物科技股份有限公司2023年第二期限制性股票激励计划实施考核管理办法
Remuneration Information Classification · 95% confidence The document is titled as the "2023 Second Phase Restricted Stock Incentive Plan Implementation Assessment Management Measures" for 圣湘生物科技股份有限公司. It details the governance, assessment criteria, performance targets, and procedures related to a restricted stock incentive plan for company executives and key personnel. The content focuses on the management and assessment of a stock incentive plan rather than financial results, board changes, or regulatory announcements. It is not a report of financial results, audit, or legal proceedings, nor is it a shareholder meeting material or voting result. It is a governance-related document concerning executive compensation and incentive mechanisms. Therefore, the most appropriate classification is Remuneration Information (DEF 14A), which covers reports detailing compensation and incentive plans for executives and directors.
2023-12-01 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2023年第四次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the procedures, attendance, and voting results of the 2023 fourth extraordinary general meeting of shareholders of a company. It details the convening, attendance, voting procedures, and results of the shareholder meeting. The document does not contain financial statements or performance data but focuses on the legal validation of the shareholder meeting and its resolutions. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms their legality.
2023-11-15 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.